DYN

Dyne Therapeutics Inc

NASDAQ: DYN · HEALTHCARE · BIOTECHNOLOGY

$18.46

-7.44% today

Updated 2026-06-05

Market cap

$3.01B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.15

Dividend yield

—

52W range

$8 – $25

Volume

1.6M

Market cap

$3.01B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.15

Dividend yield

—

52W range

$8 – $25

Volume

1.6M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

6.7

Valuation

3/9

Piotroski F-Score

Weak

0.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$38.25

+107.20%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy11 Buy2 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.02x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z 0.93 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-145.14M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-165.24M	$-235.94M	$-317.42M	$-446.21M	$-120.85M
EPS	—	—	—	—	$-3.15
Free cash flow	$-156.71M	$-188.89M	$-294.75M	$-405.13M	$-145.14M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DYN	$3.01B	37	4.3	3.0	6.7	6.5	—	Hold
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Dyne Therapeutics Inc trades at $18.46. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 0.93, it sits in the distress.

Frequently asked questions

What is Dyne Therapeutics Inc's stock price?

Dyne Therapeutics Inc (DYN) trades at $18.46.

Is Dyne Therapeutics Inc overvalued?

Dyne Therapeutics Inc carries a Smart Value Score of 37/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Dyne Therapeutics Inc (DYN)?

The 12-month analyst consensus target is $38.25, about 107.2% above the current $18.46. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Dyne Therapeutics Inc's Altman Z-Score is 0.93, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-58.90%

Beta1.08

50D MA$18.25

200D MA$17.56

Shares out0.17B

Float0.16B

Short ratio—

Avg volume1.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

DYN vs LLY →DYN vs JNJ →DYN vs ABBV →Stock screener →